| 前收盘价格 | 0.529 |
| 收盘价格 | 0.529 |
| 成交量 | 455,804 |
| 平均成交量 (3个月) | 2,776,783 |
| 市值 | 51,869,092 |
| 价格/销量 (P/S) | 247.76 |
| 股市价格/股市净资产 (P/B) | 0.830 |
| 52周波幅 | |
| 利润日期 | 6 Aug 2026 |
| 稀释每股收益 (EPS TTM) | -0.800 |
| 总债务/股东权益 (D/E MRQ) | 17.35% |
| 流动比率 (MRQ) | 7.80 |
| 营业现金流 (OCF TTM) | -62.16 M |
| 杠杆自由现金流 (LFCF TTM) | -37.33 M |
| 资产报酬率 (ROA TTM) | -39.82% |
| 股东权益报酬率 (ROE TTM) | -79.70% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | aTyr Pharma, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
-1.0
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -2.0 |
| 平均 | -1.00 |
|
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 2.23% |
| 机构持股比例 | 69.63% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合